GPCR Signaling and Regulation Notes
GPCR Signaling: Structure, Mechanisms, and Drug-Relevant Concepts
Cell signaling is a major target of drugs; many drugs target receptors because they bind specific signaling molecules (ligands) and can mimic or block them (agonists vs antagonists).
Focus of this lecture: G protein-coupled receptors (GPCRs) and associated G proteins, their signaling pathways, regulation, and pharmacological implications.
Receptor families and relevance:
GPCRs: largest family of cell-surface receptors in eukaryotic cells; major drug targets; ~half of known drugs affect GPCR signaling.
Other receptor types mentioned: receptor tyrosine kinases (RTKs) in cancer; guanylyl cyclase receptors; nuclear receptors (e.g., estrogen receptors) relevant to cancer.
Guanylyl cyclases come in two forms: receptor-type (membrane-bound) and soluble guanylyl cyclase (NO-activated).
First messenger examples discussed: acetylcholine (neurotransmitter) and nitric oxide (NO) as signaling molecules that regulate vascular tone and other processes.
NO signaling recap: NO is lipophilic and can cross membranes; NO stimulates soluble guanylyl cyclase to convert GTP to cyclic GMP (cGMP). This cGMP signaling mediates vasodilation (via smooth muscle relaxation).
Drugs mentioned that modulate these pathways: nitrates (e.g., nitroglycerin) generate NO; PDE5 inhibitors (e.g., sildenafil/Viagra) prolong NO-cGMP signaling by blocking cGMP breakdown.
GPCR Structure and Activation
Receptor and G protein are associated but distinct entities:
Receptor: ligand-binding pocket where the first messenger binds.
G protein: heterotrimeric complex adjacent to the receptor, composed of alpha (Gα), beta (Gβ), and gamma (Gγ) subunits.
G protein composition and states:
Trimeric G protein: Gα–GTPase activity with Gα bound to GDP when inactive; active state when GTP binds.
Inactive state: Gα–GDP associated with Gβγ.
Activation process:
Ligand binding to GPCR induces a conformational change in the receptor.
The receptor then facilitates exchange of GDP for GTP on the Gα subunit (GTP binds; nucleotide exchange is essential for activation).
GTP-bound Gα dissociates from Gβγ, and both can propagate signals.
Termination: intrinsic GTPase activity of Gα hydrolyzes GTP to GDP → Gα rejoins Gβγ → signaling ends until next stimulus.
Key enzymatic activity: Gα subunits are GTPases; the hydrolysis of GTP to GDP is the built-in off switch for GPCR signaling.
Important conceptual point: the alpha subunit is typically the main signaling effector in many pathways, though the beta-gamma dimer also transmits signals in several contexts.
GPCR Signaling Pathways in Specific Cell Types
Endothelial cells and vascular smooth muscle (NO vasodilation pathway):
Nerve signaling: acetylcholine released from nerves binds to M3 muscarinic receptor (a GPCR) on endothelial cells.
GPCR activation leads to a conformational change that activates the associated G protein.
Gα activates phospholipase C (PLC) → lipid cleavage:
IP3 (IP3) opens IP3-gated Ca²⁺ channels in the endoplasmic reticulum (ER) → Ca²⁺ release into cytosol.
Increased Ca²⁺ signaling activates nitric oxide synthase (NOS) in endothelial cells → NO production.
NO diffuses to adjacent smooth muscle and stimulates soluble guanylyl cyclase → conversion of GTP to cGMP:
cGMP activates a downstream target (commonly described as protein kinase G, PKG) leading to smooth muscle relaxation and vasodilation.
The NO/cGMP pathway is a common target for vasodilator drugs (nitrates, PDE5 inhibitors).
Important note from the transcript: the NO pathway is linked to vasodilation and is a common drug target; it explicitly mentions nitrates and Viagra as pharmacological examples.
Sensory neurons and pain modulation (opioid GPCR signaling):
Mu opioid receptor (MOR, including mu-1 and mu-2) is a GPCR involved in analgesia.
Upon agonist binding (e.g., endogenous endorphins or exogenous morphine/opiates), the receptor activates the heterotrimeric G protein.
The GTP-bound Gα and Gβγ subunits dissociate:
The βγ subunit role: blocks voltage-gated calcium channels, reducing Ca²⁺ influx and thus decreasing release of the neurotransmitter Substance P, leading to analgesia.
The α subunit can also participate in other signaling branches, but in this example the βγ-mediated calcium channel blockade is key to analgesia.
Termination via GTP hydrolysis and reassociation to the inactive complex.
Concept: this illustrates how different pathways (endothelial NO signaling vs neuronal analgesia) can utilize the same GPCR family but recruit different G protein subunits for distinct outcomes.
G Protein Subtypes and Signaling Diversity
Major G protein families (as discussed):
Gq: typically activates phospholipase C (PLC) leading to IP3/DAG production and Ca²⁺ signaling (as described in the endothelial pathway).
Gi: inhibits adenylyl cyclase, reducing cAMP levels.
Gs: activates adenylyl cyclase, increasing cAMP levels.
Alpha subunit focus: often the critical signaling effector; beta-gamma subunits can also produce meaningful downstream effects (e.g., voltage-gated Ca²⁺ channels in MOR signaling).
Desensitization, Tachyphylaxis, and Receptor Regulation
Tachyphylaxis: rapid reduction in drug effect with repeated dosing of the same GPCR-targeting drug.
Caused by receptor desensitization and downregulation.
Mechanisms of desensitization and downregulation:
G protein-coupled receptor kinase (GRK) phosphorylates the activated GPCR.
Arrestin binds phosphorylated receptors, blocking interaction with G proteins and initiating receptor internalization.
Internalized receptors can be recycled back to the membrane or degraded (leading to downregulation).
Clinical relevance: desensitization and downregulation contribute to tolerance to opioids and other GPCR-targeted drugs.
Visualizing the process: constant stimulation leads to receptor phosphorylation → arrestin binding → desensitized receptor → internalization → possible degradation → reduced receptor availability (downregulation).
Disease and Pathophysiology Linked to GPCR Regulation
Cholera toxin and persistent GPCR signaling (Gαs):
Cholera toxin catalyzes ADP-ribosylation of the Gα subunit, decreasing its GTPase activity.
The toxin uses NAD+ as a donor; ADP-ribose is covalently attached to Gα, locking it in the GTP-bound (active) state.
Consequence: sustained activation of adenylyl cyclase, excess production of cAMP, and downstream activation of PKA leads to chloride ion secretion and water efflux into the intestinal lumen, causing severe diarrhea and dehydration.
Mechanistic summary:
persistent activation ofClinical consequence: life-threatening dehydration if untreated.
Ras: a monomeric (not heterotrimeric) GTPase with a crucial role in cancer signaling
Ras is a small GTPase that also uses GTP/GDP state cycling:
The GTPase activity turns itself off; mutations can disable this off-switch.
Oncogenic mutation example: a single-point mutation Glycine to Valine in Ras (G12V, a classic example) reduces GTPase activity, causing Ras to remain GTP-bound and constitutively active, promoting uncontrolled cell growth.
Prevalence data mentioned (as provided in the transcript) for Ras mutations across cancers (percentages refer to various cancer types):
Head and neck cancer: ~5%
Melanoma: ~5%
Lung cancer: ~29%
Pancreatic cancer: ~32%
Colorectal cancer: ~86%
Other/unspecified category: ~41%
Note: Ras is a monomeric GTPase, not a trimeric GPCR-associated G protein; its mutation-driven constitutive signaling is a major cancer driver and a long-standing drug target.
Drug-targeting implications (RAS and beyond):
For a long time, RAS was considered undruggable because it binds GTP very tightly and lacks obvious pockets for small molecules to disrupt binding.
Recent strategies focus on discovering pockets that can accommodate small molecules to induce conformational changes that suppress Ras activity, or to disrupt Ras-effector interactions.
The general principle: identify pockets where small molecules can bind and modulate protein conformation to “turn off” the signaling driver.
The transcript notes that several Ras-targeting compounds entered clinical trials, reflecting advances in drug discovery for previously undruggable targets.
Practical Drug-Pathway Connections and Examples
NO-cGMP pathway agonists and modulators:
Nitrates (e.g., nitroglycerin) donate NO, stimulating guanylyl cyclase and increasing cGMP to cause vasodilation.
PDE5 inhibitors (e.g., sildenafil/Viagra) prevent breakdown of cGMP, prolonging vasodilation.
This illustrates how GPCR-initiated NO signaling interfaces with downstream second messengers and how pharmacological intervention can amplify or sustain the response.
Receptor targeting and pharmacology: why GPCRs are major drug targets
Drugs can mimic natural ligands (agonists) or block them (antagonists) at GPCRs.
Receptor regulation (desensitization, internalization, downregulation) influences efficacy and duration of action, contributing to tolerance.
Signaling cross-talk relevance to cancer and beyond:
GPCR pathways intersect with RTKs and nuclear receptors in complex signaling networks that drive cancer, inflammation, and metabolism.
Understanding these pathways supports targeted therapy development and explains why combination therapies may be necessary.
Key Terminology and Concepts to Remember
GPCR: G protein-coupled receptor.
G protein: heterotrimeric complex (Gα, Gβ, Gγ) that relays signals from GPCRs to downstream effectors.
GDP/GTP cycle: inactive vs active states of Gα; switching triggered by receptor stimulation and intrinsic GTPase activity.
PLC and IP3/DAG signaling: Gα (often Gq) activates PLC → IP3 and DAG; IP3 triggers Ca²⁺ release from ER.
Ca²⁺ and NOS: increased Ca²⁺ can activate NOS, producing NO.
NO and cGMP pathway: NO activates soluble guanylyl cyclase → cGMP → PKG → vasodilation.
Ach and M3 receptor: acetylcholine acts on M3 GPCR to initiate NO signaling in endothelium.
βγ subunit signaling: can regulate ion channels (e.g., voltage-gated Ca²⁺ channels) and neurotransmitter release.
β-arrestin and GRKs: mediate desensitization and internalization of GPCRs after phosphorylation.
Tachyphylaxis and downregulation: reduced drug response due to receptor desensitization and/or degradation.
Cholera toxin mechanism: ADP-ribosylation of Gα subunit reduces GTPase activity → constitutive Gs signaling → ↑cAMP → ↑Cl⁻ secretion.
Ras: monomeric GTPase; oncogenic mutations (e.g., G12V) lock Ras in active GTP-bound state; high prevalence across multiple cancers; historically viewed as undruggable but new pockets and strategies are being explored.
Practical drug examples: nitrates, PDE5 inhibitors, morphine/other opioids.
Note on a minor terminology point in the transcript: the lecturer sometimes refers to PKa in the context of cGMP signaling. The canonical pathway is cGMP activating PKG (protein kinase G), not PKA (protein kinase A). The notes above follow the established literature (PKG) but retain the transcript’s mention where relevant for exam familiarity.
Quick Recap for Exam Readiness
GPCRs are central drug targets; activation involves ligand binding, receptor conformational change, and GTP exchange on Gα.
The Gα subunit’s GTPase activity provides a built-in off switch; hydrolysis to GDP returns the G protein to the inactive state and reassembles the heterotrimer.
Different G protein classes (Gq, Gi, Gs) lead to distinct second messenger cascades (IP3/DAG/Ca²⁺, decreased cAMP, or increased cAMP, respectively).
Downstream second messengers (IP3, DAG, Ca²⁺, cAMP, cGMP) propagate signals that regulate vascular tone, pain signaling, secretion, and more.
Desensitization and downregulation are essential concepts explaining drug tolerance and receptor regulation in chronic treatment.
Clinically relevant examples illustrate how these pathways are targeted by drugs (NO donors, nitrates, PDE5 inhibitors, opioids) and how mutations (e.g., Ras) drive disease and present challenges/opportunities for therapy.
Jeopardy-Style Questions to Test Yourself
What happens to GPCR signaling when GRK phosphorylates the receptor and arrestin binds?
How does cholera toxin alter Gαs signaling to cause diarrhea?
Why are Ras mutations a major concern in cancer, and how did drug discovery approaches evolve to target Ras?
Compare Gs, Gi, and Gq pathways in terms of their main second messengers and downstream effects.
If you want, I can convert these notes into a compact cheat-sheet or create a diagram-driven guide highlighting the signaling cascades and the drug targets within each pathway.
Exam Questions on GPCR Signaling
Describe the key steps involved in the activation of a G protein-coupled receptor (GPCR) and its associated heterotrimeric G protein upon ligand binding. What are the roles of GDP and GTP in this process?
Explain the 'off-switch' mechanism that terminates GPCR signaling. What is the crucial enzymatic activity involved, and how does it lead to G protein reassembly?
Compare and contrast the GPCR signaling pathways in endothelial cells (leading to vasodilation) and sensory neurons (leading to pain modulation). Specifically, discuss the role of different G protein subunits and downstream effectors in each scenario.
Identify and briefly describe the primary downstream effects associated with the major G protein families: Gq, Gi, and Gs. Provide an example second messenger for each pathway.
Define tachyphylaxis and receptor desensitization in the context of GPCRs. Elaborate on the molecular mechanisms involving G protein-coupled receptor kinase (GRK) and arrestin that contribute to these phenomena.
Explain how cholera toxin disrupts normal GPCR signaling. What specific Gα subunit is affected, what are the biochemical consequences, and how does this lead to the clinical symptoms of cholera?
Discuss the significance of Ras mutations in cancer. How do oncogenic Ras mutations alter its normal function as a GTPase, and why was Ras historically considered an 'undruggable' target? Describe recent strategies for targeting Ras in cancer therapy.
Outline the pharmacological mechanisms by which nitrates (e.g., nitroglycerin) and PDE5 inhibitors (e.g., sildenafil) exert their vasodilatory effects. Where do these drugs intervene in the NO-cGMP signaling pathway?
What is the main role of the Gβγ subunit in the mu opioid receptor (MOR) signaling pathway that contributes to analgesia? How does this differ from typical Gα subunit-mediated signaling?
A patient is prescribed a new GPCR-targeting drug for chronic pain. Over time, the patient reports reduced efficacy of the drug, requiring higher doses for the same effect. Propose two distinct molecular mechanisms that could explain this observation.